胡桃叶提取物通过调节高脂肪饮食养小鼠的脂质基因表达和肠道微生物群来改善超脂血症
Yuanyuan Gao1,2, Jing Liu1,2, Xiaojuan Liu1,2
1College of Food Science and Engineering, Northwest A&F University, Yangling, People's Republic of China.
Journal of the science of food and agriculture
|April 1, 2025
概括
胡桃叶提取物 (PLE) 有效降低血脂,并减少过脂症小鼠的炎症. 它通过调节脂质代谢基因和恢复肠道微生物群平衡来实现这一目标,为管理高胆固醇提供一种自然的方法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 超脂血症的特点是血脂水平升高,这对健康构成重大风险.
- 胡桃叶提取物 (PLE) 已知具有药理作用,包括降脂作用.
- 红叶的精确低脂性机制在很大程度上仍未被阐明.
研究的目的:
- 为了确定桃叶提取物 (PLE) 中的关键成分.
- 在高脂肪饮食诱导的高脂血症小鼠模型中研究PLE的低脂血症机制.
- 探索PLE对脂质基因表达和肠道微生物群组成的影响.
主要方法:
- 使用高分辨率液态染色学-电喷射电离-并联质谱学 (HRLC-ESI-MS/MS) 和高性能液态染色学 (HPLC) 识别PLE组合物.
- 血清脂质,肝损伤,脂质积累和炎症标志物的评估在补充PLE的超脂症小鼠中.
- 对脂质基因表达 (FAS,ACC,SCD1,SREBP-1c,PPAR-α,CYP7A1) 和肠道微生物群组成 (16SrRNA测序) 的分析.
主要成果:
- 在PLE中确定了27种化合物,其中阿斯特拉加林,高酸,甲基素,酸和氨酸是主要的低脂成分.
- 补充PLE显著降低了血清脂质,肝损伤,脂质积累和炎症.
- 通过降低合成基因 (FAS,ACC,SCD1,SREBP-1c) 和提高降解基因 (PPAR-α,CYP7A1) 的调节,PLE调节了脂质代谢,恢复了短链脂肪酸水平,并通过降低Firmicutes/Bacteroidetes比率和增加有益细菌来改善肠道微生物群平衡.
结论:
- 红叶提取物 (PLE) 在预防和治疗超脂性大鼠的脂质代谢障碍方面表现出有效性.
- PLE调节肠道微生物群的稳态,有助于其低脂效应.
- 这项研究强调PLE是预防和管理高脂血症的有希望的天然物质.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741